Woburn, Massachusetts-based HD LifeSciences, LLC has named industry veteran Patrick O’Donnell its President and Chief Executive Officer.
HD LifeSciences Names Patrick O’Donnell President and CEO

HD LifeSciences is a spinal interbody fusion device company. The company’s portfolio includes its Hive™ product line, which are 3D-printed interbody fusion cages with its proprietary Soft Titanium™ technology. These devices offer “ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration—all features that lead to consistently strong fusion constructs and efficacious clinical experiences.” The company’s proprietary technology has been shown to reduce stiffness, provide superior imaging, and promote ingrowth and outgrowth.
O’Donnell will lead HD LifeSciences’ business operations, with an emphasis on the company’s commercial, clinical, and product development strategy. He brings over 25 years’ experience in medical devices, orthobiologics, and biomaterials in the orthopedics, spine, neurosurgery, and sports medicine fields. O’Donnell has previously held CEO, executive sales, and marketing positions at medical device and combination product companies. He began his career at DePuy Spine and subsequently held roles at early-stage, clinical stage, and pre-commercial stage companies.
OTW spoke with O’Donnell, who expressed his excitement about joining the HD LifeSciences team. “The company has been quite successful, through its early years of development, having established a strong foundation for growth both in terms of innovative technology and intellectual property as well as commercially by way of generating a staunchly loyal base of surgeon customers.”
O’Donnell continued, “I am very excited about the opportunity to roll up my sleeves and work with the team to evolve our strategy and properly focus resources to maximize the company’s growth potential and value.”
Tim Helfet, Managing Director at HD LifeSciences, said of O’Donnell’s appointment, “Patrick’s extensive strategic development and execution experiences combined with his organization team-building and commercial leadership will bring tremendous value to HD LifeSciences during this exciting time in the company’s growth.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.